Cardiometabolic disease remains the largest cause of morbidity and mortality worldwide. Marea is harnessing large-scale human genetic data and adipocyte biology to develop first-in-class treatments that target critical and unaddressed drivers of cardiometabolic diseases.

Led by a renowned team of scientific founders, clinical advisors and biopharma executives, we aim to leverage the latest advances in human genetic data to identify, create and develop novel therapies to make a significant impact for the millions of people living with cardiometabolic diseases. These are patients who need new types of medicines because they remain at high risk despite the best currently available therapies.

New mechanisms are urgently needed to treat cardiometabolic diseases at their source. Existing therapies are primarily focused on managing symptoms with few approved treatment approaches targeting the underlying biology of cardiometabolic diseases.

Marea is a clinical-stage company with a growing pipeline of first-in-class therapies to address genetically-validated cardiometabolic disease targets.

Our therapies have the potential to complement existing therapies and serve as transformative treatment options for significant patient populations living with cardiometabolic diseases.

Our Team

Marea is a fast-growing company looking for extraordinary individuals to join our team who want to make a difference in the lives of millions of people living with cardiometabolic diseases.

One of the last frontiers of cardiovascular risk: remnant cholesterol.

Marea was founded with the ambitious goal to solve a big problem: to combine robust human genetics and a focus on adipose biology to develop novel therapies for patients at risk for heart attacks even after controlling for classical risk factors such as obesity and elevated LDL cholesterol. Marea focuses on the risk that is strongly linked to an inability to properly store excess energy safely thus leading to very high rates of atherosclerotic heart disease and diabetes. These patients can be identified by routine measurement of elevated levels of so-called remnant cholesterol – a highly atherogenic lipid particle circulating in the blood. Marea is advancing a genetically validated therapy to address the underlying adipose dysfunction which then leads to elevated remnant cholesterol and metabolic dysfunction and ultimately risk for heart attack.

Remnant cholesterol is a critical atherogenic lipid driving cardiometabolic risk in more than five million patients in the U.S. alone. Remnant cholesterol is the cholesterol carried by triglyceride-rich lipoproteins and drives risk of cardiovascular disease independent of classical risk factors like LDL cholesterol, diabetes or obesity. There are no available targeted therapies to lower remnant cholesterol.